Key takeaways
- Ignore the “from $39” price. That is the membership; the drug is usually billed on top. The number that matters is the all-in monthly cost.
- The cheapest route depends entirely on your coverage, not on which brand you pick: insurance or Medicaid (if covered) beats cash, and cash-pay ranges from about $199 to $850 a month.
- Compounded is the cheapest cash option but is not FDA-approved, so it is a price-versus-safety tradeoff, not a free lunch.
If you have shopped for a GLP-1, you have seen the same trick everywhere: a big “from $39/month” headline. That number is almost always the membership fee. The medication, the part that costs real money, is billed separately. So the advertised price and the price you pay can differ by hundreds of dollars a month.
This guide cuts through that. Below is every legitimate route to a GLP-1 in 2026, with the real all-in cost of each, who it is cheapest for, and the catch to watch.
How to read these numbers
The cash figures come from our own price index, where we track advertised self-pay prices on the dates we check them and never back-fill data. Prices move, so the live comparison page is always more current than any number frozen into an article. Insurance copays, Medicaid, and Medicare costs depend on your specific coverage. This is cost reporting, not medical or financial advice.
Source: StudyBackedHealth GLP-1 price index, self-pay prices verified June 2026. Insurance and Medicaid costs vary by plan and state.
Every route at a glance
| Route | Typical monthly cost | FDA-approved drug? | Best for |
|---|---|---|---|
| Commercial insurance | $0 to ~$100 copay (if covered) | Yes (brand) | Insured, drug on your formulary |
| Medicaid | $0 or minimal (if your state covers it) | Yes (brand) | Covering states (varies a lot) |
| Medicare $50 Bridge | $50 flat | Yes (brand) | Medicare + obesity, 2026 to 2027 |
| Buy brand direct (NovoCare / LillyDirect) | ~$199 to $499 cash | Yes (brand) | Cash, want brand, skip the membership |
| Brand via telehealth | ~$199 to $850 all-in cash | Yes (brand) | Cash, want guidance and convenience |
| Compounded via telehealth | ~$99 to $299 all-in cash | No | Lowest cash cost, accepts the tradeoff |
The coverage routes (almost always the cheapest)
Commercial insurance. If your plan covers a GLP-1 for weight loss and the drug is on its formulary, you pay a copay, often somewhere between nothing and about $100 a month. The catch is access, not price: most plans require prior authorization, and denials are common. A denial is not the end of the road, and many are overturned. Our free prior-authorization and appeal-letter templates give you an evidence-based starting point.
Medicaid. If your state’s Medicaid covers GLP-1s for obesity, your cost is usually $0 or close to it. The problem is that coverage varies enormously by state, and several states added or dropped it across 2025 and 2026. We track it state by state, with each state’s official drug list, on the GLP-1 coverage by state page.
The new Medicare $50 Bridge. Starting July 1, 2026, eligible Medicare beneficiaries can get Wegovy, Zepbound, or Foundayo for a flat $50 a month through December 2027. There are real catches (the $50 does not count toward your out-of-pocket cap, and it is temporary), which we cover in the Medicare Bridge explainer.
The cash routes (if you are not covered)
Buy the brand drug direct from the manufacturer. Novo Nordisk (NovoCare, for Wegovy) and Eli Lilly (LillyDirect, for Zepbound) sell self-pay vials directly, roughly $199 to $499 a month depending on the drug and dose, with no telehealth membership layered on top. If you want the real, FDA-approved brand and do not need a program around it, this is often the cleanest cash path. Confirm the current price on each program’s site, since they change.
Brand through a telehealth program. This is where the “from” price is most misleading. The membership is cheap; the brand drug is billed separately, so the all-in cost is what counts. As of June 2026, the all-in monthly cost across the programs we recommend ranged from about $199 (Noom) to roughly $298 (Hims & Hers), $250 (Found), $548 (Ro), and $850 (Form Health) for cash-pay. The spread is huge, and the cheapest “from” price is not the cheapest all-in. Several of these can also run the brand drug through your insurance, which changes the math entirely. Sort the live, current numbers by real all-in cost on our comparison page.
Compounded through a telehealth program. Compounded semaglutide or tirzepatide is the cheapest cash route, often around $99 to $299 a month with the drug included. But compounded GLP-1s are not FDA-approved, and the FDA has documented concerns about them. This is a genuine price-versus-safety tradeoff, not a bargain version of the same thing. We lay out what the evidence does and does not say on the compounded GLP-1 page.
So what is cheapest for you?
It comes down to your coverage, in this rough order:
- Insured with the drug covered? Your insurance copay almost always wins. Fight a denial with the appeal templates before paying cash.
- On Medicaid in a covering state? Often $0. Check your state.
- On Medicare with obesity? The $50 Bridge is the new cheapest brand option, through 2027.
- Paying cash and you want the brand? Compare buying direct against telehealth all-in costs on /compare; do not assume the lowest “from” price is the lowest real cost.
- Paying cash and cost is the deciding factor? Compounded is cheapest, but read the safety tradeoff first.
Not sure you would even qualify for a prescription? Start with our am I a candidate? check, then estimate your real monthly cost for the route that fits. The advertised number is rarely the one you pay; the all-in number is the one to plan around.
- All-in price figures: our own GLP-1 price index, advertised self-pay prices verified on the dates shown (no back-filled data). Sort the live numbers by real monthly cost on the comparison page.
- Medicare GLP-1 Bridge ($50/month, July 2026 to December 2027): see our Medicare Bridge explainer (sourced to CMS and KFF).
- Manufacturer direct-pay programs: NovoCare (Wegovy) and LillyDirect (Zepbound) self-pay pricing. Confirm current prices on each program's site, as they change.
- Compounded-route caveat (not FDA-approved): see our compounded GLP-1 comparison and the FDA sources cited there.
This article was produced using our 31-point scoring methodology; every primary source we cite across the site is collected in our consolidated bibliography. We analyze published research and consumer reviews; we do not personally test medical products. This is not medical advice. Consult a licensed clinician.